Ophthotech (OPHT) Stock: Here’s What You Need To Know

Ophthotech Corporation (NASDAQ:OPHT) On Monday, Ophthotech stock tumbled lower by 86% after it announced that its phase 3 trial in patients with wet age-related macular degeneration (Wet AMD) failed to meet the primary endpoint of the study. The stock was slaughtered immediately, causing a lot of panic selling, but for good reason. The key thing … Read more

Biotech Stock News (INO) (INCY) (NVS)

Inovio Pharmaceuticals (NASDAQ:INO) On Thursday January 28, 2016 shares of Inovio closed the day up approximately 8% after the company announced it would start to recruit for a MERS vaccine trial. MERS stands for Middle Eastern Respiratory Syndrome. This trial is being collaborated between Inovio and Gene One Life Sciences. MERS is a respiratory illness … Read more

Biotech Stock News (NVS) (AVEO) (OMER) (VTL)

Aveo Oncology (NASDAQ:AVEO) & Novartis (NYSE:NVS) On August 17, 2015 shares of Aveo reached as high as 126% in one day after the company announced a partnership with Novartis. Under the terms of the agreement Novartis will make an upfront payment to Aveo for $15 million. This is in exchange for a partnership for both … Read more

Biotech Stock News (AAVL) (AERI) (AGN) (KYTH) (RHHBY) (REGN) (PFE) (NVS)

Avalanche Biotech (NASDAQ:AAVL) Shares of Avalanche Biotech fell as much as 40% in after-hours trading on June 15, 2015 after the company announced results from its phase 2 wet-age related macular degeneration — wet-AMD — trial. The drop is huge but many investors should be assured that the drop was justified because the results were … Read more

Biotech Stock News (AZN) (AMGN) (NVS) (LLY) (HRTX) (MRK)

AstraZeneca (NYSE:AZN) & Amgen (NASDAQ:AMGN) On May 26, 2015 both AstraZeneca and Amgen announced that it would end a partnership established back in 2012 for a psoriasis drug collaboration. This collaboration established in 2012 allowed Astrazeneca to work on five antibody compounds from Amgen’s anti-inflammation drug pipeline. Amgen received an upfront payment of at least … Read more